Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib with Rituximab and Chemotherapy in Newly Diagnosed PCNSL
NCT05896007Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ruijin Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05896007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896007.